A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23, an Antibody to FGF23, in Subjects with Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)
Clinical Trial Grant
Administered By
School of Medicine
Awarded By
Ultragenyx Pharmaceutical
Start Date
July 15, 2015
End Date
November 30, 2019
Administered By
School of Medicine
Awarded By
Ultragenyx Pharmaceutical
Start Date
July 15, 2015
End Date
November 30, 2019